Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086864 | PMC |
| http://dx.doi.org/10.1161/CIRCULATIONAHA.112.105908 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antithrombotic therapy following lower extremity endovascular revascularization: The results of a survey of vascular specialists.
JVS Vasc Insights
October 2024
Division of Vascular Surgery, University of Pittsburgh.
Objective: Antithrombotic therapy improves endovascular intervention outcomes for peripheral artery disease. However, there are limited data guiding the choice and duration of these adjuvant therapies. Thus, we explored current antithrombotic prescribing preferences among vascular interventionalists, hypothesizing that there are varied and inconsistent treatment practices among providers.
View Article and Find Full Text PDFStroke in Athletes with Atrial Fibrillation: A Narrative Review.
Diagnostics (Basel)
December 2024
Hospital de Santa Cruz, 2790-134 Lisbon, Portugal.
Atrial fibrillation (AF) is the most common sustained arrhythmia, linked with a significantly heightened risk of stroke. While moderate exercise reduces AF risk, high-level endurance athletes paradoxically exhibit a higher incidence. However, their stroke risk remains uncertain due to their younger age, higher cardiovascular fitness, and lower rate of comorbidities.
View Article and Find Full Text PDFPharmacotherapeutic options for coronary thrombosis treatment: where are we today?
Expert Opin Pharmacother
January 2025
Cardiovascular Research Unit, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Introduction: Advances in pharmacotherapy for coronary thrombosis treatment and prevention have transformed the clinical outcomes of patients with coronary artery disease but increased the complexity of therapeutic decision-making. Improvements in percutaneous coronary intervention techniques and stent design have reduced the incidence of thrombotic complications, which consequently has increased the challenge of adequately powering clinical trials of novel antithrombotic strategies for efficacy outcomes. Knowledge of the pathophysiology of coronary thrombosis and the characteristics of antithrombotic drugs can help with therapeutic decisions.
View Article and Find Full Text PDFSerum lipid profiling reveals characteristic lipid signatures associated with stroke in patients with leukoaraiosis.
Sci Rep
December 2024
Bao Feng Key Laboratory of Genetics and Metabolism, Beijing, China.
Many lipid biomarkers of stroke have been identified, but the lipid metabolism in elderly patients with leukoaraiosis remains poorly understood. This study aims to explore lipid metabolic processes in stroke among leukoaraiosis patients, which could provide valuable insights for guiding future antithrombotic therapy. In a cohort of 215 individuals undergoing MRI, 13 stroke patients were matched with controls, and 48 stroke patients with leukoaraiosis were matched with 40 leukoaraiosis patients.
View Article and Find Full Text PDFValidation of a High Bleeding Risk Definition in Cancer Patients undergoing Percutaneous Coronary Intervention.
Eur J Prev Cardiol
December 2024
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Aim: Due to the absence of validated bleeding risk tools in cancer patients undergoing percutaneous coronary intervention (PCI), we aimed to validate an adapted version of the Academic Research Consortium (ARC) High Bleeding Risk (HBR) criteria.
Methods: Consecutive patients with active or remission cancer undergoing PCI between 2012 and 2022 at Mount Sinai Hospital (New York, USA) were included. Patients were considered at HBR if they met at least one of the major ARC-HBR criteria, other than cancer, or two minor criteria.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!